Quercetin prevents left ventricular hypertrophy in the Apo E knockout mouse.

Abstract

Hypercholesterolemia is a risk factor for the development of hypertrophic cardiomyopathy. Nevertheless, there are few studies aimed at determining the effects of dietary compounds on early or mild cardiac hypertrophy associated with dyslipidemia. Here we describe left ventricular (LV) hypertrophy in 12 week-old Apo E(-/-) hypercholesterolemic mice. The LV end diastolic posterior wall thickness and overall LV mass were significantly increased in Apo E(-/-) mice compared with wild type (WT) controls. Fractional shortening, LV end diastolic diameter, and hemodynamic parameters were unchanged from WT mice. Oral low dose quercetin (QCN; 0.1 µmol QCN/kg body weight for 6 weeks) significantly reduced total cholesterol and very low density lipoprotein in the plasma of Apo E(-/-) mice. QCN treatment also significantly decreased LV posterior wall thickness and LV mass in Apo E(-/-) mice. Myocardial geometry and function were unaffected in WT mice by QCN treatment. These data suggest that dietary polyphenolic compounds such as QCN may be effective modulators of plasma cholesterol and could prevent maladaptive myocardial remodeling.

• Authors: Elena Ulasova, Jessica Perez, Bradford G Hill, Wayne E Bradley, David W Garber, Aimee Landar, Stephen Barnes, Jeevan Prasain, Dale A Parks, Louis J Dell'Italia, Victor M Darley-Usmar
• Journal: Redox biology (Redox Biol) Vol. 1 Pg. 381-6 ( 2013) ISSN: 2213-2317 [Electronic] Netherlands
• PMID: 24024175 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Antioxidants
• Apolipoproteins E
• Cholesterol
• Quercetin

Topics

• Animals
• Antioxidants (administration & dosage, therapeutic use)
• Apolipoproteins E (genetics)
• Cholesterol (blood)
• Hypercholesterolemia (diet therapy, genetics, pathology)
• Hypertrophy, Left Ventricular (complications, diet therapy, physiopathology)
• Mice
• Mice, Inbred C57BL
• Mice, Knockout
• Quercetin (administration & dosage, therapeutic use)
• Ventricular Remodeling (drug effects)